SC66 is a novel and potent AKT inhibitor, which reduced cell viability in a dose- and time-dependent manner, inhibited colony formation and induced apoptosis in HCC cells. SC66 treatment led to a reduction in total and phospho-AKT levels. SC66 significantly potentiated the effects of both conventional chemotherapeutic and targeted agents, doxorubicin and everolimus, respectively. In vivo, SC66 inhibited tumor growth of Hep3B cells in xenograft models, with a similar mechanism observed in the in vitro model. SC66 had antitumor effects on HCC cells.
Related Products:
MK-2206 2HCl; Ipatasertib; Triciribine; PHT-427; Capivasertib; Perifosine; CCT128930; AT7867; AT13148; ONC-201; Akti-1/2; Miltefosine; GSK690693